Registro nacional de cáncer de próstata 2010 en España

Cózar, J.M.; Miñana, B.; Gómez-Veiga, F.; Rodrı́guez-Antolı́n, A.; Villavicencio, H.; Cantalapiedra, A.; Pedrosa, E.

doi:10.1016/j.acuro.2012.06.006

Cited by 88 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estos hallazgos son congruentes con lo observado por otros autores, que atribuyen el importante incremento de la incidencia al uso extendido de la prueba de PSA 2,15,16 . Como es sabido, la extensión de la determinación de PSA como prueba de cribado es un tema controvertido, ya que al incrementar el sobrediagnóstico no se ve un efecto claro sobre la mortalidad específica y tiene efectos negativos sobre la calidad de vida de los pacientes 16,17 .…”

Section: Discussionunclassified

“…Del mismo modo, en el quinquenio 2000-2004 la tasa de los registros españoles osci-laba entre el más bajo de Granada (49,1) y el más elevado del País Vasco (104,8) y la incidencia global media era de 86,6 mientras que en nuestra área de salud se encontraba en la zona baja de la tabla (52,3). Finalmente, nuestras cifras de incidencia en el último trienio (119) son incluso superiores a las comunicadas para el año 2012 para España (96,8 nuevos casos por 100.000 hombres) o las publicadas por Cózar para el año 2010 (70,8 ) 17 .…”

Section: Discussionunclassified

“…También se observa cómo el número de casos metastásicos se mantiene relativamente estable. El porcentaje de pacientes con enfermedad localizada en el último trienio (87,4%) es muy similar al publicado por Cózar et al 17 y ligeramente superior al encontrado en Estados Unidos (81%) 22 . El porcentaje de casos metastásicos es similar al de los estudios anteriores del 4% y en nuestro caso del 5% 17,22 .…”

Section: Discussionunclassified

See 2 more Smart Citations

Incidencia hospitalaria, tendencia y distribución municipal del cáncer de próstata en el área de salud de León (1996-2010)

Sánchez

García-Sanz²,

García-Martínez³

et al. 2015

Rev. Esp. Salud Publica

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

See 1 more Smart Citation

Incidencia hospitalaria, tendencia y distribución municipal del cáncer de próstata en el área de salud de León (1996-2010)

Sánchez

García-Sanz²,

García-Martínez³

et al. 2015

Rev. Esp. Salud Publica

View full text Add to dashboard Cite

show abstract

“…1,2 Age, family history of prostate cancer (PCa) and race factors seem to be the most important risk factors. 1,2 Age, family history of prostate cancer (PCa) and race factors seem to be the most important risk factors.…”

Section: Introductionmentioning

confidence: 99%

Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness

Fuentes-Pastor

Pellejero

Ortiz

et al. 2016

Actas Urológicas Españolas (English Edition)

View full text Add to dashboard Cite

“…These sources of information, however, do not include the type of data needed to identify the diagnostic processes, therapeutic approaches, and prognostic factors in prostate cancer. Recently, one study regarding prostate cancer has been conducted in Spain, with the objective to estimate prostate cancer incidence and profile the newly-diagnosed cases using a nationwide hospital-based registry [ 16 , 17 ]. However, this study fails to examine the diagnosis and therapeutic processes and possible factors influencing these time intervals.…”

Section: Introductionmentioning

confidence: 99%

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study

et al. 2015

View full text Add to dashboard Cite

BackgroundLittle is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment.MethodsWe conducted a multicentre, cohort study in seven hospitals in Spain. Patients’ characteristics and diagnostic and therapeutic variables were obtained from hospital records and patients’ structured interviews from October 2010 to September 2011. We used a multilevel logistic regression model to examine the association between patient care intervals and various variables influencing these intervals (age, BMI, educational level, ECOG, first specialist consultation, tumour stage, PSA, Gleason score, and presence of symptoms) and calculated the odds ratio (OR) and the interquartile range (IQR). To estimate the random inter-hospital variability, we used the median odds ratio (MOR).Results470 patients with prostate cancer were included. Mean age was 67.8 (SD: 7.6) years and 75.4 % were physically active. Tumour size was classified as T1 in 41.0 % and as T2 in 40 % of patients, their median Gleason score was 6.0 (IQR:1.0), and 36.1 % had low risk cancer according to the D’Amico classification. The median interval between first consultation and diagnosis was 89 days (IQR:123.5) with no statistically significant variability between centres. Presence of symptoms was associated with a significantly longer interval between first consultation and diagnosis than no symptoms (OR:1.93, 95%CI 1.29–2.89). The median time between diagnosis and first treatment (therapeutic interval) was 75.0 days (IQR:78.0) and significant variability between centres was found (MOR:2.16, 95%CI 1.45–4.87). This interval was shorter in patients with a high PSA value (p = 0.012) and a high Gleason score (p = 0.026).ConclusionsMost incident prostate cancer patients in Spain are diagnosed at an early stage of an adenocarcinoma. The period to complete the diagnostic process is approximately three months whereas the therapeutic intervals vary among centres and are shorter for patients with a worse prognosis. The presence of prostatic symptoms, PSA level, and Gleason score influence all the clinical intervals differently.

show abstract

Registro nacional de cáncer de próstata 2010 en España

Cited by 88 publications

References 18 publications

Incidencia hospitalaria, tendencia y distribución municipal del cáncer de próstata en el área de salud de León (1996-2010)

Incidencia hospitalaria, tendencia y distribución municipal del cáncer de próstata en el área de salud de León (1996-2010)

Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study

Contact Info

Product

Resources

About